Skip to content
Screener

Polaryx Therapeutics, Inc. PLYX Cash and cash equivalents, end of period

Cash and cash equivalents, end of period at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$145.32M+205%

Other financials

Income statement

See full
Operating income-$2.0M+61.2%
Net income-$2.5M+49.6%
EPS (diluted)-$0.05+54.5%

Balance sheet

See full
Cash & equivalents$3.1M+1,132%
Total equity$2.5M-41.5%
Total assets$3.5M

Cash flow

See full
Operating cash flow-$2.1M-191%

Valuation

See full
Market cap$112.65M-89.4%

Returns & leverage

See full
Return on equity-1,209.8%
Current ratio3.5×

Where this comes from

Reported directly by Polaryx Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The source filing: Polaryx Therapeutics, Inc.’s 10-Q, filed May 15, 2026.

Filed
May 14, 2026, 8:00 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001213900-26-056973
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Accrued expenses and other current liabilities(87)
Net cash flows used in operating activities(2,063)(709)
Cash flows from financing activities
Proceeds from issuance of common stock250
Net cash flows provided by financing activities250
Net decrease in cash and cash equivalents(2,063)(459)
Cash and cash equivalents, beginning5,1434,621
Cash and cash equivalents, ending$3,080$4,162

Item 1. Financial Statements (Unaudited) Item 1. Financial Statements

FAQ

What is Polaryx Therapeutics, Inc.'s cash and cash equivalents, end of period?
Polaryx Therapeutics, Inc. (PLYX) reported cash and cash equivalents, end of period of 308,000,000% in Q1 2026.
How has Polaryx Therapeutics, Inc.'s cash and cash equivalents, end of period changed year-over-year?
Polaryx Therapeutics, Inc.'s cash and cash equivalents, end of period decreased by 26.0% year-over-year, from 416,200,000% to 308,000,000%.
What is the long-term trend for Polaryx Therapeutics, Inc.'s cash and cash equivalents, end of period?
Over 2 years (2023 to 2025), Polaryx Therapeutics, Inc.'s cash and cash equivalents, end of period has grown at a 4971.0% compound annual growth rate (CAGR), from 200,000% to 514,300,000%.

Ask your AI about Polaryx Therapeutics, Inc.'s cash and cash equivalents, end of period.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude